Attenuated reovirus
US10668119B2 · kind B2 · utility
0Cited by
28References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 24, 2016 |
| Grant date | Jun 2, 2020 |
| Priority date | — |
| Expiry date | Aug 24, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2720/12264
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compositions and methods are provided that relate to an attenuated reovirus exhibiting oncolytic activity toward cancer cells while displaying reduced lytic activity toward non-malignant cells. Exemplified is an attenuated human reovirus derived from persistently infected fibrosarcoma cells that lacks wild-type reovirus S1 and S4 genes and consequently lacks a detectable reoviral outer capsid .sigma.1 protein and expresses a mutated reoviral outer capsid .sigma.3 protein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.